Mabtech Establishes Strategic U.S. Collaboration with Sai Life Sciences to Expand Access to EYRA(TM) Multiplex Immunology Platform

Sai Life Sciences' Boston site designated as co-marketed U.S. execution hub for Mabtech's EYRA platform, bringing high-sensitivity multiplex immune profiling to biopharma and biotech clients across ...
PE Hub

EQT takes Mabtech in first acquisition of new strategy

Biotech is our opening topic this morning as we deep dive into a double announcement from EQT. The firm is acquiring a Swedish biotech company as part of the launch of a new Healthcare Growth Strategy ...
Taiwan News

Mabtech and Sai Life Sciences Announce Strategic Collaboration to Advance Immunology Research with EYRA Platform at Sai Boston Site

BOSTON and STOCKHOLM, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mabtech, a global life science tools company specializing in advanced immunoassays, and Sai Life Sciences, a leading integrated Contract ...
Nasdaq

EQT Unveils Healthcare Buyout Strategy With Investment In Mabtech

(RTTNews) - EQT (EQT) introduced the EQT Healthcare Growth Strategy, a dedicated healthcare buyout strategy. The strategy aims to enable the development of medical research, diagnostics, tools and ...
Pharmabiz

Mabtech, Sai Life Sciences partner to advance immunology research with EYRA platform at Sai Boston site

Mabtech, a global life science tools company specializing in advanced immunoassays, and Sai Life Sciences, a leading integrated contract research, development, and manufacturing organization (CRDMO), ...
Finanznachrichten

SAI LIFE SCIENCES LIMITED: Mabtech and Sai Life Sciences Announce Strategic Collaboration to Advance Immunology Research with EYRA Platform at Sai Boston Site

BOSTON and STOCKHOLM, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mabtech, a global life science tools company specializing in advanced immunoassays, and Sai Life Sciences, a leading integrated Contract ...